Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma

Liver International

Volumn 32, Issue 10, 2012, Pages 1516-1526

  Mizukoshi, Eishiro ^a   Fushimi, Kazumi ^a   Arai, Kuniaki ^a   Yamashita, Tatsuya ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; CTL; Epitope; Immunotherapy; Peptide vaccine; Tumour associated antigen

Indexed keywords

ALPHA FETOPROTEIN; CHONDROITIN GLUCURONATE C5 EPIMERASE; CHONDROITIN GLUCURONATE C5 EPIMERASE DERIVED PEPTIDE; EPIMERASE; GAMMA INTERFERON; PEPTIDE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84867100828     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02853.x     Document Type: Article

References (34)

1. Llovet JM, Burroughs A, Bruix J Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4cm. Gastroenterology 2004; 127: 1714-23.
3. Omata M, Tateishi R, Yoshida H, Shiina S Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159-66.
4. Greten TF, Manns MP, Korangy F Immunotherapy of hepatocellular carcinoma. J Hepatol 2006; 45: 868-78.
5. Butterfield LH Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly 2007; 137: 83-90.
6. Maccarana M, Olander B, Malmstrom J, et al. Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is identical to SART2. J Biol Chem 2006; 281: 11560-8
7. Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 2565-74.
8. Noguchi M, Yao A, Harada M, et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007; 67: 933-42.
9. Terasaki M, Shibui S, Narita Y, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 337-44.
10. Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011; 53: 1206-16.
11. Itoh K, Yamada A Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 970-6.
12. Araki T, Itai Y, Furui S, Tasaka A Dynamic CT densitometry of hepatic tumors. AJR Am J Roentgenol 1980; 135: 1037-43.
13. Japan. LCSGo. Classification of Primary Liver Cancer. English ed 2. Tokyo:Kanehara & Co., Ltd. 1997.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
15. Oiso M, Eura M, Katsura F, et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer 1999; 81: 387-94.
16. Mizukoshi E, Nakamoto Y, Marukawa Y, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006; 43: 1284-94.
17. Ikeda-Moore Y, Tomiyama H, Miwa K, et al. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol 1997; 159: 6242-52.
18. Kuzushima K, Hayashi N, Kimura H, Tsurumi T Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-81.
19. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056-63.
20. Sato Y, Maeda Y, Shomura H, et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90: 1334-42.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
22. Ribas A, Butterfield LH, Glaspy JA, Economou JS Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-32.
23. Mizukoshi E, Nakamoto Y, Tsuji H, et al. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006; 118: 1194-204.
24. Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003; 9: 5902-8.
25. Butterfield LH, Ribas A, Dissette VB, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006; 12: 2817-25.
26. Fujioka M, Nakashima Y, Nakashima O, Kojiro M Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001; 34: 1128-34.
27. Maeda Y, Hida N, Niiya F, et al. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br J Cancer 2002; 87: 796-804.
28. Suzuki N, Maeda Y, Tanaka S, et al. Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 2002; 98: 45-50.
29. Tokunaga K, Ishikawa Y, Ogawa A, et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997; 46: 199-205.
30. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55: 1553-64.
31. Greten TF, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10: 209.
32. Yoshikawa T, Nakatsugawa M, Suzuki S, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102: 918-25.
33. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-43.
34. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.